Polytope monoclonal antibody therapeutics are being developed by ImmunoPrecise Antibodies (IPA) in collaboration with EVQLV for the treatment of COVID-19 infections. EVQLV, an artificial intelligence company will utilise B cell selectTM and custom DeepDisplayTM platform developed at IPA. B cell selectTM platform enables the interrogation of B-cells and generate native monoclonal antibodies from any immunised animal, independent of species. DeepDisplayTM platform is a combination of phage display platform which contains immune libraries from different animal species including transgenic animals and Ligand's OmniAb therapeutic antibody platform which develop fully human antibody with reduced immunogenicity. EVQLV will perform in-silico antibody design to discover novel antibody sequence to leverage lead candidate from IPA's discovery platform. Early research is underway in US.
In March 2020, ImmunoPrecise Antibody and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against COVID-19. Under the terms of the agreement, EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV will utilise its in-silico antibody design to generate novel antibody sequence by using IPA's B cell selectTM and custom deep displayTM technology platform to discover lead candidate against SARS-CoV-2 coronavirus infection.
Key Development Milestones
In March 2020, EVQLV submitted the first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2  .